A Randomised, Multicentre, Double-Blind, Phase 3 Study of AZD9833 (An Oral SERD) plus Palbociclib plus Anastrozole Placebo versus Anastrozole plus Palbociclib plus AZD9833 Placebo for the treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer who have not received any systemic treatment for advanced disease.
